Skip to main content

Biocom’s Hot Technology Event: Developing More Predictable 3D Cellular Cell Models

When:

August 6, 2019 11:00 amAugust 6, 2019 1:00 pm (PDT)

Where:

The Alexandria at Torrey Pines
10996 Torreyana Road
San Diego, CA 92121

Registration Closed

Join us on August 6th for Biocom's Hot Technology Event sponsored by Thermo Fisher Scientific.


Organoids, spheroids, and the study of 3D cell culture models show great potential in many applications including disease modeling and regenerative medicine. 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically relevant context where 2D models have not proven as successful. At Thermo Fisher Scientific, we look to improve advanced culture systems in order for our customers to gain confidence to culture and analyze organoids and spheroids through validated protocols and educational resources.


As part of our 3D initiative, we have been developing various models for recapitulation of more physiologically relevant systems in 3D that include scaffold-free spheroids and organoids. Those systems can be utilized in drug development and discovery and other research that requires longevity and more complex functional culture systems. We have developed them as easy to assemble systems that can be readily set up in your laboratory using readily available cell and reagents, and finally evaluated using analytical tools from Thermo Fisher Scientific.


In this seminar, the following areas of 3D research will be covered; An overview of cell line engineering capabilities including our iPSC-Cas9 cell line, Thermo’s 3D Spheroids and Organoids portfolio, our new hepatic spheroid and stellate culture systems, PSC-derived organoids and HCA analysis of 3D spheroid and organotypic models.


Moderator:

Mark Federici, Director Business Development for Bio-Innovations, Thermo Fisher Scientific

Panelists:

Kelsey Retting, Ph.D., Director, Research and Preclinical Development, Organovo


User-added image

Price of Admission

Biocom Member

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2019-07-31

0

Refund before

Refund Before

Non-Member (Industry) ONLY

Today’s Price: 30

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

30

Refund before 2019-07-31

30

Refund before

Refund Before

  • Speaker Bio
    Mark Federici

    User-added image
    • Director, Business Development for Bio-innovations
    • Associate Director, Strategic Alliance Management
    • Joined Thermo Fisher Scientific in 2006
     
    Academic Background:
    • BS, Biology, St. Joseph’s University, PA
    • MS, Biotechnology/Chemical Engineering, Manhattan College, Riverdale, NY
    • Lab Manager, Memorial Sloan Kettering Cancer Center, Dept. of Surgery, Breast and Ovarian Cancer Laboratory, (1987-2000).
    • Authored/co-authored more than 35 peer reviewed journal articles.
    • Managed Cell Biology Dept., Cell and Molecular Technologies/Sentigen (2000-2006).
    • 2) patents, Division Arrested Cells for HTS and Tango Technology for Beta Arrestin Recruitment in GPCRs
    • Positions held at Thermo Fisher Scientific: field applications scientist, technical sales specialist and collaborations manager
    • Current member of the LRRK2 Consortium, at the Michael J. Fox Foundation for Parkinson’s Disease Research. Reviewing Editor for SLAS Journal.
    • Member Thermo Fisher Scientific Drug Discovery and Stem Cell Steering Committees.  Senior leadership counsel for 3D Modeling

    Panelist: 
    Chetana Revankar, Senor Staff Scientist, Thermo Fisher Scientific 

    Chetana Revankar is a Senior Staff Scientist at Thermo Fisher Scientific, with over 20 years of experience in the field of Cell Biology and has been with the company for 12 years.  Currently she leads a group within Custom Services Team responsible for developing engineered cell lines and custom workflows for a variety of applications. Before joining the Services team, she led the development of several new products ranging from Cellular assays for GPCR, BacMam based assays to 3D cellular models. Her experience covers a broad range of applications from cell engineering to disease modeling.
     

Registration Closed